Ad
related to: what is decitabine used for medication uses and treatment- Dosing With INQOVI
Oral Dosing Schedule & What To Do
If Modifications Are Needed.
- INQOVI Efficacy & Safety
Learn About Trial Results
Including Safety & Efficacy.
- Patient Considerations
Learn Which Patients May
Be Appropriate For INQOVI.
- Why INQOVI?
Learn How INQOVI May Help Your
Patients. Access Prescribing Info.
- $0 Co-Pay Program
Learn How Your Eligible Patients
May Enroll For A $0 Co-Pay.
- Watch A Panel Discussion
See Medical Professionals & A
Patient Advocate Discuss INQOVI.
- Dosing With INQOVI
Search results
Results From The WOW.Com Content Network
Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. [4] It is a medication for the treatment of myelodysplastic syndromes , a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). [ 5 ]
Decitabine/cedazuridine, sold under the brand name Inqovi among others, is a fixed-dose combination anticancer medication used for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML).
Both compounds have been approved in the treatment of myelodysplastic syndrome (MDS) by Food and Drug Administration (FDA) in United States. Azacitidine and decitabine are marketed as Vidaza and Dacogen respectively. Azacitidine is the first drug to be approved by FDA for treating MDS and has been given orphan drug status.
Azacitidine is indicated for the treatment of myelodysplastic syndrome, [4] for which it received approval by the U.S. Food and Drug Administration (FDA) on 19 May 2004. [11] [4] [12] In two randomized controlled trials comparing azacitidine to supportive treatment, 16% of subjects with myelodysplastic syndrome who were randomized to receive azacitidine had a complete or partial normalization ...
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." Prescriptions for weight loss drugs are skyrocketing, especially among ...
Dr. Leana Wen: Both are injection medications that are intended to be used once a week. They were both first approved to treat type 2 diabetes, and clinical trials also showed that they induced a ...
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
Ad
related to: what is decitabine used for medication uses and treatment